TY  - THES
A1  - Mathew-Schmitt, Sanjana
T1  - Development of blood-brain barrier spheroid models based on human induced pluripotent stem cells (hiPSCs) and investigation of shear stress on hiPSC-derived brain capillary endothelial-like cells
T1  - Entwicklung von Sphäroid-Modellen der Blut-Hirn-Schranke basierend auf 
menschlichen induzierten pluripotenten Stammzellen (hiPSCs) und Untersuchung der Scherbeanspruchung von hiPSC-abgeleiteten Hirnkapillarendothel-ähnlichen Zellen
N2  - A highly regulated microenvironment is essential in maintaining normal functioning of the central nervous system (CNS). The existence of a biological barrier, termed as the blood-brain barrier (BBB), at the blood to brain interface effectively allows for selective passage of substances and pathogens into the brain (Kadry, Noorani et al. 2020). The BBB chiefly serves in protecting the brain from extrinsic toxin entry and pathogen invasions. The BBB is formed mainly by brain capillary endothelial cells (BCECs) which are responsible for excluding ∼ 100% of large-molecule neurotherapeutics and more than 98% of all small-molecule drugs from entry into the brain. Minimal BBB transport of major potential CNS drugs allows for attenuated effective treatments for majority of CNS disorders (Appelt-Menzel, Oerter et al. 2020). Animals are generally used as model systems to study neurotherapeutic delivery into the brain, however due to species based disparity, experimental animal models lead to several false positive or false negative drug efficacy predictions thereby being unable to fully predict effects in humans (Ruck, Bittner et al. 2015). An example being that over the last two decades, much of the studies involving animals lead to high failure rates in drug development with ~ 97% failure in cancers and ~ 99% failure for Alzheimer´s disease (Pound 2020). Widespead failures in clinical trials associated with neurological disorders have resulted in questions on whether existing preclinical animal models are genuinely reflective of the human condition (Bhalerao, Sivandzade et al. 2020). Apart from high failure rates in humans, the costs for animal testings is extremely high. According to the Organisation for Economic Co-operation and Development (OECD), responsible for determining animal testing guidelines and methodology for government, industry, and independent laboratories the average cost of a single two-generation reproductive animal toxicity study worldwide is 318,295 € and for Europe alone is ~ 285,842 € (Van Norman 2019). Due to these reasons two separate movements exist within the scientific world, one being to improve animal research and the other to promote new approach methodologies with the European government setting 2025 - 2035 as a deadline for gradually disposing the use of animals in pharmaceutical testing (Pound 2020).
The discovery of human induced pluripotent stem cell (hiPSC) technology in 2006 (Takahashi and Yamanaka 2006, Takahashi, Tanabe et al. 2007) revolutionized the field of drug discovery in-vitro. HiPSCs can be differentiated into various tissue types that mimic disease phenotypes, thereby offering the possibility to deliver humanized in-vitro test systems. With respect to the BBB, several strategies to differentiate hiPSCs to BCECs (iBCECs) are reported over the years (Appelt-Menzel, Oerter et al. 2020). However, iBCECs are said to possess an epithelial or undifferentiated phenotype causing incongruity in BBB lineage specifications (Lippmann,
7
Azarin et al. 2020). Therefore, in order to identify a reliable differentiation strategy in deriving iBCECs possessing hallmark BBB characteristics, which can be used for downstream applications, the work in this thesis compared two methods, namely the co-differentiation (CD) and the directed differentiation (DD). Briefly, CD mimics a brain like niche environment for iBCEC specification (Lippmann, Al-Ahmad et al. 2014), while DD focuses on induction of the mesoderm followed by iBCEC specification (Qian, Maguire et al. 2017). The results obtained verified that while iBCECs derived via CD, in comparison to human BCEC cell line hCMEC/D3 showed the presence of epithelial transcripts such as E-Cadherin (CDH1), and gene level downregulation of endothelial specific platelet endothelial cell adhesion molecule-1 (PECAM-1) and VE-cadherin (CDH5) but demonstrated higher barrier integrity. The CD strategy essentially presented iBCECs with a mean trans-endothelial electrical resistance (TEER) of ~ 2000 – 2500 Ω*cm2 and low permeability coefficients (PC) of < 0.50 μm/min for small molecule transport of sodium fluorescein (NaF) and characteristic BCEC tight junction (TJ) protein expression of claudin-5 and occludin. Additionally, iBCECs derived via CD did not form tubes in response to angiogenic stimuli. DD on the other hand resulted in iBCECs with similar down regulations in PECAM-1 and CDH5 gene expression. They were additionally characterized by lower barrier integrity, measured by mean TEER of only ~ 250 – 450 Ω*cm2 and high PC of > 5 μm/min in small molecule transport of NaF. Although iBCECs derived via DD formed tubes in response to angiogenic stimuli, they did not show positive protein expression of characteristic BCEC TJs such as claudin-5 and occludin. These results led to the hypothesis that maturity and lineage specification of iBCECs could be improved by incorporating in-vivo like characteristics in-vitro, such as direct co-culture with neurovascular unit (NVU) cell types via spheroid formation and by induction of shear stress and fluid flow. In comparison to standard iBCEC transwell mono-cultures, BBB spheroids showed enhanced transcript expression of PECAM-1 and reduced expression of epithelial markers such as CDH1 and claudin-6 (CLDN6). BBB spheroids showed classical BCEC-like ultrastructure that was identified by TJ particles on the protoplasmic face (P-face) and exoplasmic face (E-face) of the plasma membrane. TJ strands were organized as particles and particle-free grooves on the E-face, while on the P-face, partly beaded particles and partly continuous strands were identified. BBB spheroids also showed positive protein expression of claudin-5, VE-cadherin, PECAM-1, glucose transporter-1 (GLUT-1), P-glycoprotein (P-gp) and transferrin receptor-1 (Tfr-1). BBB spheroids demonstrated higher relative impedance percentages in comparison to spheroids without an iBCEC barrier. Barrier integrity assessments additionally corresponded with lower permeability to small molecule tracer NaF, with spheroids containing iBCECs showing higher relative fluorescence unit percentages (RFU%) of ~ 90% in apical compartments, compared to ~ 80% in spheroids without iBCECs. In summary, direct cellular contacts in the complex spheroid model resulted in enhanced maturation of iBCECs.
8
A bioreactor system was used to further assess the effect of shear stress. This system enabled inclusion of fluidic flow and shear stress conditions in addition to non-invasive barrier integrity measurements (Choi, Mathew et al. 2022). iBCECs were cultured for a total of seven days post differentiation (d17) within the bioreactor and barrier integrity was non-invasively monitored. Until d17 of long-term culture, TEER values of iBCECs steadily dropped from ~ 1800 Ω*cm2 ~ 400 Ω*cm2 under static conditions and from ~ 2500 Ω*cm2 to ~ 250 Ω*cm2 under dynamic conditions. Transcriptomic analyses, morphometric analyses and protein marker expression showed enhanced maturation of iBECs under long-term culture and dynamic flow. Importantly, on d10 claudin-5 was expressed mostly in the cytoplasm with only ~ 5% iBCECs showing continuous staining at the cell borders. With increase in culture duration, iBCECs at d17 of static culture showed ~ 18% of cells having continuous cell border expression, while dynamic conditions showed upto ~ 30% of cells with continuous cell-cell border expression patterns. Similarly, ~ 33% of cells showed cell-cell border expression of occludin on d10 with increases to ~ 55% under d17 static and up to ~ 65% under d17 dynamic conditions, thereby indicating iBCEC maturation.
In conclusion, the data presented within this thesis demonstrates the maturation of iBCECs in BBB spheroids, obtained via direct cellular contacts and by the application of flow and shear stress. Both established novel models need to be further validated for pharmaceutical drug applications together with in-vitro-in-vivo correlations in order to exploit their full potential.
N2  - Eine hochregulierte Mikroumgebung ist für die Aufrechterhaltung der normalen Funktion des Zentralen Nervensystems (ZNS) unerlässlich. Das Vorhandensein einer biologischen Barriere, der so genannten Blut-Hirn-Schranke (BHS), als Schnittstelle zwischen Blutkreislauf und Gehirn ermöglicht den selektiven Durchgang von Substanzen und Pathogenen in das Gehirn (Kadry, Noorani et al. 2020). Die BHS dient hauptsächlich dazu, das Gehirn vor dem Eindringen von Toxinen von außen und dem Eindringen von Krankheitserregern zu schützen. Die BHS wird hauptsächlich von Hirnkapillarendothelzellen (engl. brain capillary endothelial cells, BCECs) gebildet, die dafür verantwortlich sind, dass ∼ 100% der großmolekularen Neurotherapeutika und mehr als 98% aller kleinmolekularen Medikamente nicht in das Gehirn gelangen können. Ein eingeschränkter BHS-Transport wichtiger potenzieller Wirkstoffe führt zu einer abgeschwächten Wirksamkeit der Behandlung der meisten ZNS-Erkrankungen (Pardridge 2005). Mäuse, Ratten, Schweine und Rinder werden in der Regel als Modellsysteme verwendet, um die Verabreichung von Neurotherapeutika in das Gehirn zu untersuchen. Aufgrund der Unterschiede zwischen den Spezies führen experimentelle Tiermodelle jedoch vermehrt zu falsch positiven oder falsch negativen Vorhersagen über die Wirksamkeit von Medikamenten, so dass sie nicht in der Lage sind, die Wirkungen beim Menschen vollständig vorherzusagen (Ruck, Bittner et al. 2015). Ein Beispiel dafür ist, dass in den letzten zwei Jahrzehnten ein Großteil der Studien an Tieren zu Misserfolgsraten in der Wirkstoffzulassung geführt hat. Bei einer Fehlerrate von 97% im Zusammenhang mit Krebs und ~99% bei Alzheimer führt dies zum Therapieversagen (Pound 2020). Die weit verbreiteten Misserfolge bei klinischen Versuchen im Zusammenhang mit neurologischen Erkrankungen haben zu der Frage geführt, ob die bestehenden präklinischen Tiermodelle wirklich die Physiologie des Menschen widerspiegeln (Bhalerao, Sivandzade et al. 2020). Abgesehen von den hohen Ausfallraten sind die Kosten für Tierversuche extrem hoch. Nach Angaben der Organisation für wirtschaftliche Zusammenarbeit und Entwicklung (engl. Organisation for Economic Co-operation and Development, OECD), welche für die Festlegung von Tierversuchsrichtlinien und -methoden für die Regierung, die Industrie und unabhängige Labore zuständig ist, belaufen sich die durchschnittlichen Kosten für eine einzige Zwei-Generationen-Studie zur Reproduktionstoxizität an Tieren weltweit auf 318.295 € und allein für Europa auf ~ 285.842 € (Van Norman 2019). Aus diesen Gründen gibt es zwei unterschiedliche Bemühungen unter den Wissenschaftlern. Zum einen zur Verbesserung der Tierforschung und zum anderen zur Förderung neuer Methoden gemäß den 3R (eng. replace, reduce, refine), wobei die europäische Regierung die Jahre 2025 bis 2035 als Frist für den schrittweisen Verzicht auf Tierversuche in der Forschung festgelegt hat (Pound 2020). Die
10
Entdeckung der humanen induziert pluripotenten Stammzell (hiPSC)-Technologie im Jahr 2006 (Takahashi und Yamanaka 2006, Takahashi, Tanabe et al. 2007) hat den Bereich der Arzneimittelforschung revolutioniert, da hiPSCs in verschiedene Gewebetypen differenziert werden können und damit die Möglichkeit bieten, humanisierte in-vitro-Testsysteme bereitzustellen, die zur Untersuchung verschiedener Krankheiten verwendet werden können.
In Bezug auf die BHS wurde im Laufe der Jahre mehrere Strategien zur Differenzierung von hiPSCs zu BCECs (iBCECs) etabliert (Appelt-Menzel, Oerter et al. 2020), allerdings wird ihnen ein epithelialer Phänotyp nachgesagt, was zu Fragen in der Spezifikation der BBB führt (Lippmann, Azarin et al. 2020). Um eine verlässliche Differenzierungsstrategie für die Gewinnung von iBCECs mit charakteristischen BHS-Merkmalen zu finden, welche für Downstream-Anwendungengenutztwerden können, wurden in dieser Arbeit zwei Methoden verglichen. Die Ko-Differenzierung (engl. co-differentiation, CD) und die gerichtete Differenzierung (engl. directed differentiation, DD). Zusammengefasst simuliert die CD eine ZNS-ähnliche Mikroumgebung für die Spezifikation der iBCECs nach (Lippmann, Al-Ahmad et al. 2014), während sich die DD auf die Induktion des Mesoderms und die anschließende iBCEC-Spezifikation konzentriert (Qian, Maguire et al. 2017). Die erzielten Ergebnisse bestätigten, dass iBCECs, welche mittels CD abgeleitet wurden, im Vergleich zur humanen BCEC-Zelllinie (hCMEC/D3) zwar epitheliale Transkripte wie E-Cadherin (CDH1) besitzen, aber eine Herabregulierung von Thrombozyten-Endothelzell-Adhäsionsmolekül-1 (PECAM-1) und VE-Cadherin (CDH5) aufweisen. Die von CD abgeleiteten iBCECs hatten zudem eine höhere Barriere-Integrität und Funktionalität gezeigt. Im Wesentlichen führte die CD-Strategie zu iBCECs mit einem hohen transendothelialen elektrischen Widerstand (engl. Transendothelialelectrical resistance, TEER) von 2000 - 2500Ω*cm2, einem niedrigen Permeabilitätskoeffizienten (eng. Permeability co-efficient, PC) von < 0,50 μm/min für den Transport kleiner Moleküle wie Natriumfluorescein (NaF) und einer charakteristischen Expression von BCEC-spezifischen Tight Junction (TJ)-Proteinen wie Claudin-5 und Occludin. Außerdem bildeten iBCECs, welche über CD gewonnen wurden, keine Gefäßstrukturen als Reaktion auf angiogene Stimuli. DD hingegen führte zu iBCECs mit einer ähnlichen Herabregulierung der PECAM-1- und CDH5-Genexpression, die zusätzlich durch eine geringere Barriereintegrität, gemessen an einem niedrigen TEER von nur ~ 250 - 450 Ω*cm2 und einem hohen PC von > 5 μm/min, bei dem Transport von NaF gekennzeichnet war. Obwohl die über DD gewonnenen iBCECs in der Lage waren Gefäßnetze auszubilden, zeigten sie keine Expression der charakteristischen BCEC-TJs wie Claudin-5 und Occludin.
Diese Ergebnisse führten zu der Hypothese, die in-vitro Differenzierung und Reifung von iBCECs zu verbessern, indem in-vivo-ähnliche Stimuli in-vitro angewandt werden, wie z. B. die direkte Kokultur mit Zelltypen der neurovaskulären Einheit (NVE) durch Sphäroidbildung und die Induktion von Scherstress in einem dynamischen Flussmodell. Im Vergleich zu iBCEC-
11
basierten Transwellmodellen, die zumeist in Monokulturen aufgebaut werden, zeigten die BHS-Sphäroide eine erhöhte Expression von PECAM-1 und eine reduzierte Expression von Epithelmarkern wie E-Cadherin (CDH1) und Claudin-6 (CLDN6). BHS-Sphäroide zeigten eine klassische BCEC-ähnliche Ultrastruktur, die durch TJ-Partikel auf der protoplasmatischen Phase (P-Phase) und der exoplasmatischen Phase (E-Phase) der Plasmamembran gekennzeichnet war. Die TJ-Stränge waren als Partikel und partikelfreie Rillen auf der E-Phase organisiert, während auf der P-Phase teils Partikel und teils kontinuierliche Stränge zu erkennen waren. BHS-Sphäroide zeigten auch eine positive Proteinexpression von Claudin-5, VE-Cadherin, PECAM-1, Glukose-Transporter-1 (GLUT-1), P-Glykoprotein (P-gp) und Transferrin-Rezeptor-1 (Tfr-1). Die BHS-Sphäroide wiesen ebenfalls höhere relative Impedanzwerte im Vergleich zu Sphäroiden ohne iBCEC-Barriere auf. Die Bewertung der Integrität der Barriere korrespondierte zudem mit einer geringeren Permeabilität für den niedermolekularen Tracer NaF, wobei Sphäroide mit iBCECs einen höheren Prozentsatz an relativen Fluoreszenzeinheiten (RFU%) von etwa 90% in den apikalen Kompartimenten aufwiesen, verglichen mit etwa 80% in Sphäroiden ohne iBCECs. Zusammenfassend lässt sich sagen, dass direkte zelluläre Kontakte im komplexen Sphäroidmodell zu einer verstärkten Reifung von iBCECs führten.
In-vivo ist die BHS Scherbelastungen ausgesetzt, die einen wichtigen und oft vernachlässigten physiologischen Stimulus darstellen (Cucullo, Hossain et al. 2011). Um die Auswirkung von Scherstress auf die Eigenschaften und die Reifung von iBCECs zu messen, wurden diese in einem Bioreaktorsystem kultiviert.(Choi, Mathew et al. 2022). Hier war es möglich, iBCECs für insgesamt sieben Tage nach der Differenzierung (d17) erfolgreich in diesem System zu kultivieren und zusätzlich die Barriereintegrität nicht-invasiv zu überwachen. Bis d17 der Langzeitkultur fielen die TEER-Werte von iBCECs stetig von ~ 1800 Ω*cm2 ~ 400 Ω*cm2 unter statischen Bedingungen bzw. von ~ 2500 Ω*cm2 auf ~ 250 Ω*cm2 unter dynamischen Bedingungen. Zusätzliche Untersuchungen und Vergleiche von iBCECs unter diesen Kulturbedingungen mittels transkriptioneller und morphometrischer Analysen, sowie Expression von Proteinmarkern zeigten, dass iBCECs aufgrund der Langzeitkultur und des dynamischen Flusses eine verstärkte Reifung vorweisen. Wichtig ist, dass Claudin-5 bei d10 hauptsächlich im Zytoplasma exprimiert wurde und nur etwa 5% der iBCECs eine kontinuierliche Färbung an den Zellgrenzen aufwiesen. Mit zunehmender Kulturdauer zeigten iBCECs bei d17 in statischer Kultur ~ 18% der Zellen mit kontinuierlicher Zellrandexpression, während unter dynamischen Bedingungen bis zu ~ 30% der Zellen kontinuierliche Zellrandexpressionsmuster aufwiesen. In ähnlicher Weise zeigten ~ 33% der Zellen eine Zell-Zell-Grenzexpression von Occludin an d10 mit einem Anstieg auf ~ 55% unter d17 statischen und bis zu ~ 65% unter d17 dynamischen Bedingungen, was auf eine iBCEC-Reifung hinweist. Zusammenfassend zeigen die in dieser Arbeit vorgestellten Daten die Reifung von iBCECs in
12
BHS Sphäroiden, die durch direkte Zell - Zell Kontakte und in dynamischen Strömungsmodellen durch die Anwendung von Scherspannungen erreicht wird. Beide etablierten neuen Modelle müssen für pharmazeutische Anwendungen zusammen mit In-vitro-in-vivo-Korrelationen weiter validiert werden, um ihr volles Potential zu beweisen.
KW  - Blut-Hirn-Schranke
KW  - Blood-brain barrier
Y1  - 2024
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-322475
ER  - 
TY  - THES
A1  - Gamboa Vargas, Juan Fernando
T1  - Receptors of the TNFSF in the biology and regulation of Tregs
T1  - Rezeptoren der TNFSF in der Biologie und Regulation von regulatorischen T-Zellen
N2  - In this work we expanded upon a study from our group where a ligand-based TNF-α mutein was developed to engage specifically TNFR2 and not TNFR1 activating Tregs and expanding them, which in an allo-HCT context conferred protection from GvHD. Fusing TNF trimers to the heavy chain of an Fc-dead and mouse irrelevant antibody, a new generation of this agonist was developed called NewSTAR2. It is believed that other members of the TNFSF can also target Tregs, therefore additional agonists against DR3 and GITR were developed under the same principles as for NewSTAR2. Phenotyping analysis of the expression of these three receptors were done to confirm their specificity for Tregs before in vitro and in vivo testings with mice or murine splenic cells. A potent expansion of Tregs was seen with NewSTAR2 and the other agonists as well as upregulation of activation markers on Tregs. Thorough analyses with NewSTAR2-treated mice showed how Tregs in several immune and non-immune organs were expanded and upregulated immunomodulatory receptors. A miniature suppressive assay and other cocultures with responder cells confirmed their enhanced suppression over unstimulated Tregs through contact dependent and independent mechanisms. Despite other myeloid cells also being increased after treatment, no undesired effects were observed under steady-state and prophylactic administration of a single dose of NewSTAR2 improved survival frequencies and lessened development of clinical symptoms. Prophylactic treatment with the other TNFRSF agonists showed similar protection yet Fc(DANA)-muTL1A was superior in in terms of less death events and lower clinical score. It was found that not all the three TNFSF members have redundant functions as development of skin lesions was observed with GITRL-based agonist Fc(DANA)-muGITRL, although its expansion of Tregs in steady-state was remarkable with no apparent adverse effects. Neither agonist had an impact on donor cell engraftment or allorective T cell response, however NewSTAR2-treatmend proved to reduce inflammation in small intestine and liver. This work is proof of concept of the effectivity of selectively engaging TNFSF to activate Tregs and expand them systemically allowing them to control strong and complex immune interactions like those governing GvHD.
N2  - In dieser Arbeit erweiterten wir eine Studie unserer Gruppe, in der ein ligandenbasiertes TNF-α-Mutein entwickelt wurde, um spezifisch TNFR2 und nicht TNFR1 zu aktivieren und Tregs zu erweitern, was in einem allo-HCT-Kontext Schutz vor GvHD verlieh. Durch die Fusion von TNF-Trimeren mit der schweren Kette eines Fc-toten und Maus-irrelevanten Antikörpers wurde eine neue Generation dieses Agonisten namens NewSTAR2 entwickelt. Es wird angenommen, dass andere Mitglieder des TNFSF ebenfalls auf Tregs abzielen können. Daher wurden zusätzliche Agonisten gegen DR3 und GITR nach denselben Prinzipien wie für NewSTAR2 entwickelt. Eine phänotypische Analyse der Expression dieser drei Rezeptoren wurde durchgeführt, um ihre Spezifität für Tregs vor In-vitro- und In-vivo-Tests mit Mäusen oder murinen Milzzellen zu bestätigen. Bei NewSTAR2 und den anderen Agonisten wurde eine starke Expansion der Tregs sowie eine Hochregulierung der Aktivierungsmarker auf Tregs beobachtet. Gründliche Analysen mit NewSTAR2-behandelten Mäusen zeigten, wie Tregs in mehreren Immun- und Nichtimmunorganen erweitert und immunmodulatorische Rezeptoren hochreguliert wurden. Ein Miniatur-Suppressionstest und andere Kokulturen mit Responderzellen bestätigten deren verstärkte Unterdrückung nicht stimulierter Tregs durch kontaktabhängige und unabhängige Mechanismen. Obwohl auch andere myeloische Zellen nach der Behandlung zunahmen, wurden unter der Steady-State- und prophylaktischen Verabreichung einer Einzeldosis NewSTAR2 keine unerwünschten Wirkungen beobachtet, was die Überlebenshäufigkeit verbesserte und die Entwicklung klinischer Symptome verringerte. Die prophylaktische Behandlung mit den anderen TNFRSF-Agonisten zeigte einen ähnlichen Schutz, Fc(DANA)-muTL1A war jedoch in Bezug auf weniger Todesereignisse und einen niedrigeren klinischen Score überlegen. Es wurde festgestellt, dass nicht alle drei TNFSF-Mitglieder über redundante Funktionen verfügen, da die Entwicklung von Hautläsionen mit dem GITRL-basierten Agonisten Fc(DANA)-muGITRL beobachtet wurde, obwohl die Expansion der Tregs im Steady-State bemerkenswert war und keine offensichtlichen nachteiligen Auswirkungen auftrat. Keiner der beiden Agonisten hatte einen Einfluss auf die Transplantation von Spenderzellen oder die allorektive T-Zell-Reaktion, allerdings reduzierte die NewSTAR2-Behandlung nachweislich Entzündungen im Dünndarm und in der Leber. Diese Arbeit ist ein Beweis für die Wirksamkeit der selektiven Aktivierung von TNFSF, um Tregs zu aktivieren und sie systemisch zu erweitern, sodass sie starke und komplexe Immuninteraktionen steuern können, wie sie GvHD steuern.
KW  - Regulatorischer T-Lymphozyt
KW  - Transplantat-Wirt-Reaktion
KW  - Tumor-Nekrose-Faktor
KW  - TNFRSF
KW  - Regulatory T cells
KW  - Graft versus host disease
KW  - Tumornekrosefaktor Rezeptor-Superfamilie
KW  - Regulatorische T-Zellen
KW  - Transplantat-gegen-Wirt-Reaktion
Y1  - 2024
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-369801
ER  - 
TY  - JOUR
A1  - Calderon, Dayana
A1  - Peña, Luis
A1  - Suarez, Angélica
A1  - Villamil, Carolina
A1  - Ramirez-Rojas, Adan
A1  - Anzola, Juan M.
A1  - García-Betancur, Juan C.
A1  - Cepeda, Martha L.
A1  - Uribe, Daniel
A1  - Del Portillo, Patricia
A1  - Mongui, Alvaro
T1  - Recovery and functional validation of hidden soil enzymes in metagenomic libraries
JF  - MicrobiologyOpen
N2  - The vast microbial diversity on the planet represents an invaluable source for identifying novel activities with potential industrial and therapeutic application. In this regard, metagenomics has emerged as a group of strategies that have significantly facilitated the analysis of DNA from multiple environments and has expanded the limits of known microbial diversity. However, the functional characterization of enzymes, metabolites, and products encoded by diverse microbial genomes is limited by the inefficient heterologous expression of foreign genes. We have implemented a pipeline that combines NGS and Sanger sequencing as a way to identify fosmids within metagenomic libraries. This strategy facilitated the identification of putative proteins, subcloning of targeted genes and preliminary characterization of selected proteins. Overall, the in silico approach followed by the experimental validation allowed us to efficiently recover the activity of previously hidden enzymes derived from agricultural soil samples. Therefore, the methodology workflow described herein can be applied to recover activities encoded by environmental DNA from multiple sources.
KW  - environmental microbiology
KW  - functional genomics
KW  - metagenomics
KW  - microbial genomics
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-222016
VL  - 8
ER  - 
TY  - JOUR
A1  - Germain, Dominique P.
A1  - Brand, Eva
A1  - Burlina, Alessandro
A1  - Cecchi, Franco
A1  - Garman, Scott C.
A1  - Kempf, Judy
A1  - Laney, Dawn A.
A1  - Linhart, Aleš
A1  - Maródi, László
A1  - Nicholls, Kathy
A1  - Ortiz, Alberto
A1  - Pieruzzi, Federico
A1  - Shankar, Suma P.
A1  - Waldek, Stephen
A1  - Wanner, Christoph
A1  - Jovanovic, Ana
T1  - Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study
JF  - Molecular Genetics & Genomic Medicine
N2  - Background
The p.Asn215Ser or p.N215S GLA variant has been associated with late-onset cardiac variant of Fabry disease.

Methods
To expand on the scarce phenotype data, we analyzed natural history data from 125 p.N215S patients (66 females, 59 males) enrolled in the Fabry Registry (NCT00196742) and compared it with data from 401 patients (237 females, 164 males) harboring mutations associated with classic Fabry disease. We evaluated interventricular septum thickness (IVST), left ventricular posterior wall thickness (LVPWT), estimated glomerular filtration rate and severe clinical events.

Results
In p.N215S males, mildly abnormal mean IVST and LVPWT values were observed in patients aged 25–34 years, and values gradually increased with advancing age. Mean values were similar to those of classic males. In p.N215S females, these abnormalities occurred primarily in patients aged 55–64 years. Severe clinical events in p.N215S patients were mainly cardiac (males 31%, females 8%) while renal and cerebrovascular events were rare. Renal impairment occurred in 17% of p.N215S males (mostly in patients aged 65–74 years), and rarely in females (3%).

Conclusion
p.N215S is a disease-causing mutation with severe clinical manifestations found primarily in the heart. Cardiac involvement may become as severe as in classic Fabry patients, especially in males.
KW  - cardiac variant
KW  - Fabry disease
KW  - GLA
KW  - p.Asn215Ser
KW  - p.N215S
KW  - phenotype
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-232976
VL  - 6
ER  - 
TY  - JOUR
A1  - Kaspar-Ott, Irena
A1  - Hertig, Elke
A1  - Kaspar, Severin
A1  - Pollinger, Felix
A1  - Ring, Christoph
A1  - Paeth, Heiko
A1  - Jacobeit, Jucundus
T1  - Weights for general circulation models from CMIP3/CMIP5 in a statistical downscaling framework and the impact on future Mediterranean precipitation
JF  - The International Journal of Climatology
N2  - This study investigates the projected precipitation changes of the 21st century in the Mediterranean area with a model ensemble of all available CMIP3 and CMIP5 data based on four different scenarios. The large spread of simulated precipitation change signals underlines the need of an evaluation of the individual general circulation models in order to give higher weights to better and lower weights to worse performing models. The models' spread comprises part of the internal climate variability, but is also due to the differing skills of the circulation models. The uncertainty resulting from the latter is the aim of our weighting approach. Each weight is based on the skill to simulate key predictor variables in context of large and medium scale atmospheric circulation patterns within a statistical downscaling framework for the Mediterranean precipitation. Therefore, geopotential heights, sea level pressure, atmospheric layer thickness, horizontal wind components and humidity data at several atmospheric levels are considered. The novelty of this metric consists in avoiding the use of the precipitation data by itself for the weighting process, as state-of-the-art models still have major deficits in simulating precipitation. The application of the weights on the downscaled precipitation changes leads to more reliable and precise change signals in some Mediterranean sub-regions and seasons. The model weights differ between sub-regions and seasons, however, a clear sequence from better to worse models for the representation of precipitation in the Mediterranean area becomes apparent.
KW  - CMIP3
KW  - CMIP5
KW  - Mediterranean area
KW  - precipitation
KW  - statistical downscaling
KW  - weights
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-325628
VL  - 39
ER  - 
TY  - JOUR
A1  - Mirza, Myriam
A1  - Vainshtein, Anna
A1  - DiRonza, Alberto
A1  - Chandrachud, Uma
A1  - Haslett, Luke J.
A1  - Palmieri, Michela
A1  - Storch, Stephan
A1  - Groh, Janos
A1  - Dobzinski, Niv
A1  - Napolitano, Gennaro
A1  - Schmidtke, Carolin
A1  - Kerkovich, Danielle M.
T1  - The CLN3 gene and protein: What we know
JF  - Molecular Genetics & Genomic Medicine
N2  - Background
One of the most important steps taken by Beyond Batten Disease Foundation in our quest to cure juvenile Batten (CLN3) disease is to understand the State of the Science. We believe that a strong understanding of where we are in our experimental understanding of the CLN3 gene, its regulation, gene product, protein structure, tissue distribution, biomarker use, and pathological responses to its deficiency, lays the groundwork for determining therapeutic action plans.

Objectives
To present an unbiased comprehensive reference tool of the experimental understanding of the CLN3 gene and gene product of the same name.

Methods
BBDF compiled all of the available CLN3 gene and protein data from biological databases, repositories of federally and privately funded projects, patent and trademark offices, science and technology journals, industrial drug and pipeline reports as well as clinical trial reports and with painstaking precision, validated the information together with experts in Batten disease, lysosomal storage disease, lysosome/endosome biology.

Results
The finished product is an indexed review of the CLN3 gene and protein which is not limited in page size or number of references, references all available primary experiments, and does not draw conclusions for the reader.

Conclusions
Revisiting the experimental history of a target gene and its product ensures that inaccuracies and contradictions come to light, long-held beliefs and assumptions continue to be challenged, and information that was previously deemed inconsequential gets a second look. Compiling the information into one manuscript with all appropriate primary references provides quick clues to which studies have been completed under which conditions and what information has been reported. This compendium does not seek to replace original articles or subtopic reviews but provides an historical roadmap to completed works.
KW  - Batten
KW  - CLN3
KW  - JNCL
KW  - juvenile Batten
KW  - neuronal ceroid lipofuscinosis
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-224138
VL  - 7
ER  - 
TY  - JOUR
A1  - Jandke, Solveig
A1  - Garz, Cornelia
A1  - Schwanke, Daniel
A1  - Sendtner, Michael
A1  - Heinze, Hans-Jochen
A1  - Carare, Roxana O.
A1  - Schreiber, Stefanie
T1  - The association between hypertensive arteriopathy and cerebral amyloid angiopathy in spontaneously hypertensive stroke-prone rats
JF  - Brain Pathology
N2  - We aimed to test the hypothesis that in spontaneously hypertensive stroke-prone rats (SHRSP), non-amyloid cerebral small vessel disease/hypertensive arteriopathy (HA) results in vessel wall injury that may promote cerebral amyloid angiopathy (CAA). Our study comprised 21 male SHRSP (age 17–44 weeks) and 10 age- and sex-matched Wistar control rats, that underwent two-photon (2PM) imaging of the arterioles in the parietal cortex using Methoxy-X04, Dextran and cerebral blood flow (CBF) measurements. Our data suggest that HA in SHRSP progresses in a temporal and age-dependent manner, starting from small vessel wall damage (stage 1A), proceeding to CBF reduction (stage 1B), non-occlusive (stage 2), and finally, occlusive thrombi (stage 3). Wistar animals also demonstrated small vessel wall damage, but were free of any of the later HA stages. Nearly half of all SHRSP additionally displayed vascular Methoxy-X04 positivity indicative of cortical CAA. Vascular β-amyloid deposits were found in small vessels characterized by thrombotic occlusions (stage 2 or 3). Post-mortem analysis of the rat brains confirmed the findings derived from intravital 2PM microscopy. Our data thus overall suggest that advanced HA may play a role in CAA development with the two small vessel disease entities might be related to the same pathological spectrum of the aging brain.
KW  - cerebral amyloid angiopathy
KW  - cerebral small vessel disease
KW  - hypertensive arteriopathy
KW  - intravital imaging
KW  - spontaneously hypertensive stroke-prone rat
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-323279
VL  - 28
ER  - 
TY  - JOUR
A1  - Moll, Julia
A1  - Kellner, Harald
A1  - Leonhardt, Sabrina
A1  - Stengel, Elisa
A1  - Dahl, Andreas
A1  - Bässler, Claus
A1  - Buscot, François
A1  - Hofrichter, Martin
A1  - Hoppe, Björn
T1  - Bacteria inhabiting deadwood of 13 tree species are heterogeneously distributed between sapwood and heartwood
JF  - Environmental Microbiology
N2  - Deadwood represents an important structural component of forest ecosystems, where it provides diverse niches for saproxylic biota. Although wood-inhabiting prokaryotes are involved in its degradation, knowledge about their diversity and the drivers of community structure is scarce. To explore the effect of deadwood substrate on microbial distribution, the present study focuses on the microbial communities of deadwood logs from 13 different tree species investigated using an amplicon based deep-sequencing analysis. Sapwood and heartwood communities were analysed separately and linked to various relevant wood physico-chemical parameters. Overall, Proteobacteria, Acidobacteria and Actinobacteria represented the most dominant phyla. Microbial OTU richness and community structure differed significantly between tree species and between sapwood and heartwood. These differences were more pronounced for heartwood than for sapwood. The pH value and water content were the most important drivers in both wood compartments. Overall, investigating numerous tree species and two compartments provided a remarkably comprehensive view of microbial diversity in deadwood.
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-224168
VL  - 20
ER  - 
TY  - JOUR
A1  - Hilmers, Torben
A1  - Friess, Nicolas
A1  - Bässler, Claus
A1  - Heurich, Marco
A1  - Brandl, Roland
A1  - Pretzsch, Hans
A1  - Seidl, Rupert
A1  - Müller, Jörg
T1  - Biodiversity along temperate forest succession
JF  - Journal of Applied Ecology
N2  - 1.
The successional dynamics of forests—from canopy openings to regeneration, maturation, and decay—influence the amount and heterogeneity of resources available for forest-dwelling organisms. Conservation has largely focused only on selected stages of forest succession (e.g., late-seral stages). However, to develop comprehensive conservation strategies and to understand the impact of forest management on biodiversity, a quantitative understanding of how different trophic groups vary over the course of succession is needed.

2.
We classified mixed mountain forests in Central Europe into nine successional stages using airborne LiDAR. We analysed α- and β-diversity of six trophic groups encompassing approximately 3,000 species from three kingdoms. We quantified the effect of successional stage on the number of species with and without controlling for species abundances and tested whether the data fit the more-individuals hypothesis or the habitat heterogeneity hypothesis. Furthermore, we analysed the similarity of assemblages along successional development.

3.
The abundance of producers, first-order consumers, and saprotrophic species showed a U-shaped response to forest succession. The number of species of producer and consumer groups generally followed this U-shaped pattern. In contrast to our expectation, the number of saprotrophic species did not change along succession. When we controlled for the effect of abundance, the number of producer and saproxylic beetle species increased linearly with forest succession, whereas the U-shaped response of the number of consumer species persisted. The analysis of assemblages indicated a large contribution of succession-mediated β-diversity to regional γ-diversity.

4.
Synthesis and applications. Depending on the species group, our data supported both the more-individuals hypothesis and the habitat heterogeneity hypothesis. Our results highlight the strong influence of forest succession on biodiversity and underline the importance of controlling for successional dynamics when assessing biodiversity change in response to external drivers such as climate change. The successional stages with highest diversity (early and late successional stages) are currently strongly underrepresented in the forests of Central Europe. We thus recommend that conservation strategies aim at a more balanced representation of all successional stages.
KW  - biodiversity
KW  - forest dynamics
KW  - forest succession
KW  - habitat heterogeneity
KW  - LiDAR
KW  - species density
KW  - temperate forests
KW  - β-diversity
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-320632
VL  - 55
ER  - 
TY  - JOUR
A1  - Kwok, Chee Keong
A1  - Ueda, Yuichiro
A1  - Kadari, Asifiqbal
A1  - Günther, Katharina
A1  - Ergün, Süleyman
A1  - Heron, Antoine
A1  - Schnitzler, Aletta C.
A1  - Rook, Martha
A1  - Edenhofer, Frank
T1  - Scalable stirred suspension culture for the generation of billions of human induced pluripotent stem cells using single-use bioreactors
JF  - Journal of Tissue Engineering and Regenerative Medicine
N2  - The production of human induced pluripotent stem cells (hiPSCs) in quantities that are relevant for cell-based therapies and cell-loaded implants through standard adherent culture is hardly achievable and lacks process scalability. A promising approach to overcoming these hurdles is the culture of hiPSCs in suspension. In this study, stirred suspension culture vessels were investigated for their suitability in the expansion of two hiPSC lines inoculated as a single cell suspension, with a free scalability between volumes of 50 and 2400 ml. The simple and robust two-step process reported here first generates hiPSC aggregates of 324 ± 71 μm diameter in 7 days in 125 ml spinner flasks (100 ml volume). These are subsequently dissociated into a single cell suspension for inoculation in 3000 ml bioreactors (1000 ml volume), finally yielding hiPSC aggregates of 198 ± 58 μm after 7 additional days. In both spinner flasks and bioreactors, hiPSCs can be cultured as aggregates for more than 40 days in suspension, maintain an undifferentiated state as confirmed by the expression of pluripotency markers TRA-1-60, TRA-1-81, SSEA-4, OCT4, and SOX2, can differentiate into cells of all three germ layers, and can be directed to differentiate into specific lineages such as cardiomyocytes. Up to a 16-fold increase in hiPSC quantity at the 100 ml volume was achieved, corresponding to a fold increase per day of 2.28; at the 1000 ml scale, an additional 10-fold increase was achieved. Taken together, 16 × 106 hiPSCs were expanded into 2 × 109 hiPSCs in 14 days for a fold increase per day of 8.93. This quantity of hiPSCs readily meets the requirements of cell-based therapies and brings their clinical potential closer to fruition.
KW  - bioprocessing
KW  - human pluripotent stem cells
KW  - process optimization
KW  - single-use bioreactors
KW  - stirred suspension culture
KW  - scalable culture system
Y1  - 2018
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-234545
VL  - 12
ER  -